Why SELLAS Life Sciences Group, Inc. (SLS) stock rose 156.4% on Tuesday, November 17, 2026
SELLAS Life Sciences Group, Inc. (SLS) closed at $19.15, up 156.36% on Tuesday, November 17, 2026, on volume of 116,644,883 shares (16.7× its 3-month average); market value about $3.90B, according to Nexqual market data (nexqual.com/moves/2026-11-17/SLS).
What happened: primary sources
Events Nexqual found for SLS on Tuesday, November 17, 2026 or the trading day before (November 16, 2026), each linked to its primary source:
- Nov 17, 2026: SEC 8-K: Other material event source
Quoted from the filing: “On November 17, 2026, the Company issued the Press Release announcing positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating GPS, an immunotherapeutic cancer vaccine, in patients with AML. The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to…”
These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.
More on SLS
SLS stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 17, 2026.
Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 18, 2026 at 20:31 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 18, 2026 at 20:31 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt